CHMP recommends dengue vaccine for children
Takeda’s novel dengue vaccine has received positive opinion from the EMA’s human medicines committee (CHMP), demonstrating the vaccine is safe for patients from four years old.
List view / Grid view
Takeda’s novel dengue vaccine has received positive opinion from the EMA’s human medicines committee (CHMP), demonstrating the vaccine is safe for patients from four years old.
Sanofi’s Japan-based manufacturing site near Tokyo will be sold to a European contract development and manufacturing organisation.
CHMP issues positive opinion on Pluvicto®, paving the way for it to become the first European-approved radioligand therapy for metastatic prostate cancer patients.
A new Phase II trial will study the drug ENT-01 for Parkinson’s Disease (PD)-associated dementia at sites in the UK and US.
Results from a clinical study by Astellas have demonstrated the effectiveness of fezolinetant as a treatment for menopause-associated VMS.
MIT researchers have developed a robotic capsule that tunnels through mucus in the GI tract to deliver large oral protein-based drugs like insulin.
Five health technology assessment (HTA) bodies will collaborate with NICE to help resolve regulatory and digital health technology challenges.
The oral medication Hydromethylthionine mesylate (HMTM) is the first anti-tau disease-modifying therapy to offer sustained cognitive improvement in Alzheimer’s.
The new methodology will assess the carbon impact of clinical trials and recommend ways to reduce it.
A University of Cambridge report assessing the preferred relationship type between pharma and contract research organisations (CROs), showed strategic partnerships will continue as the primary collaboration model.
The UK Government’s Vaccine Taskforce (VTF) has funded CPI’s innovative training academy and manufacturing facility to further the development of novel RNA therapies and vaccines.
The FDA has approved Boostrix, the first vaccine for pregnant women in their third trimester, to stop whooping cough (Pertussis) in infants below two months.
The natural compound tigilanol tiglate was produced in a lab for the first time by scientists at Stanford University, suggesting it could provide treatment for a variety of cancers.
NICE has recommended the drug Zeposia® (ozanimod) for moderate to severe cases of ulcerative colitis.
Outsourcing the production of oral solids is estimated to be the primary influencer for the contract manufacturing market in the next decade, using lessons learnt from the COVID-19 pandemic.